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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the benefits and harms of granulocyte colony-stimulating factor with or without stem or progenitor cell infusion in people with
compensated or decompensated advanced chronic liver disease.
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B A C K G R O U N D
Description of the condition
DiHerent etiologies of liver disease, such as viral infection, toxin
exposure, alcohol abuse, and metabolic, immunological, or genetic
diseases, cause continuous and repeated damage to the liver.
Persistent injury leads to inflammation, progressive fibrosis,
and compensatory hepatocyte hyperplasia, usually culminating
in cirrhosis that is characterised by distortion of the hepatic
architecture and the formation of regenerative nodules. The
histological pattern is generally considered to be irreversible, and
the disease is usually asymptomatic until complications develop
(Garcia-Tsao 2010; Tsochatzis 2014). The clinical identification of
cirrhosis is imperfect and requires a liver biopsy and histology.
Liver stiHness measurement (LSM) by transient elastography and
use of biomarkers are non-invasive accurate tests for the diagnosis
of severe fibrosis and cirrhosis (Foucher 2006; Pavlov 2015). It
has been proposed that the term 'advanced chronic liver disease'
should be used as an alternative to 'cirrhosis' (de Franchis 2015).
Advanced chronic liver disease is characterised by a long
compensated phase, with median survival from diagnosis of
around 12 years (d'Amico 2006). This asymptomatic phase,
termed 'compensated', is followed by a rapidly progressive phase,
termed 'decompensated', which is marked by the development
of complications of portal hypertension and/or liver dysfunction.
In the compensated phase, portal pressure may be normal.
As the disease progresses, portal pressure increases and liver
function decreases, resulting in the development of ascites,
portal hypertensive gastrointestinal bleeding, encephalopathy,
and jaundice. The development of any of these complications
marks the transition from a compensated to a decompensated
phase. Progression may be accelerated by the development
of other complications such as (re)bleeding, renal impairment
(refractory ascites, hepatorenal syndrome), hepatopulmonary
syndrome, and sepsis (spontaneous bacterial peritonitis). The
development of hepatocellular carcinoma (HCC) may accelerate
the course of the disease at any stage. When decompensation
occurs, expected median survival is around two years (d'Amico
2006; d'Amico 2014).
Globally, advanced chronic liver disease is considered responsible
for more than one million deaths annually (Rowe 2017). The
geographical distribution of liver disease is non-uniform and
reflects the diHerent prevalence of risk factors including alcohol
consumption, hepatitis C virus (HCV) infection, hepatitis B virus
infection, obesity, and the metabolic syndrome. In 2010, advanced
chronic liver disease accounted for approximately 49,500 deaths
and was the eighth leading cause of death in the United States
(Murray 2013). A recent European Association for the Study of
Liver Disease (EASL) report from 35 European countries estimated
a median age-adjusted prevalence of chronic liver disease of 833
people per 100,000. Following data from 2017, prevalence ranged
from a minimum of 447 people per 100.000 in Iceland to a maximum
of 1100 per 100.000 in Romania, with a total of 151,513 deaths
from liver disease in European countries (Pimpin 2018). In 2012, in
England, people with liver disease admitted to a hospital were more
likely to die compared to people classified as all-cause admissions
(8.8% versus 1.4%) (NICE 2016).
Description of the intervention
No treatment is available to specifically target fibrosis and cirrhosis,
and liver transplantation remains the only curative option (Rossi
2007). Many researchers are investigating strategies to restore liver
functionality to avoid or slow progression towards end-stage liver
disease, ultimately requiring a rescue liver transplantation.
Cell therapy is an emerging strategy that aims to restore
liver functionality; in particular, bone marrow-derived stem cells
(BMSCs) seem to be able to contribute to liver regeneration and to
diHerentiate into hepatocyte-like cells (Forbes 2011; Thomas 2011).
These stem cells can be infused, can reach the liver, and can become
hepatocytes, improving liver function (Forbes 2016). Furthermore,
cytokine mobilisation of BMSCs from the bone marrow to the liver
could improve liver function (Alison 2000). Granulocyte colony-
stimulating factor (G-CSF) is a 175-amino-acid protein, obtained
through recombinant DNA technology and currently available for
mobilisation of haematopoietic stem cells (HSCs) from the bone
marrow (Moore 2014; Lanthier 2018). The minimum recommended
dosage needed to obtain peripheral cell mobilisation is 5 mcg/kg
daily, for at least five consecutive days (Alison 2000; Duong 2014).
How the intervention might work
Multiple courses of G-CSF have been shown to modulate
inflammation, mobilise HSCs, increase hepatocyte growth factor,
and induce hepatic progenitor cells to proliferate within seven
days of administration (Spahr 2008; Gilchrist 2010; Gaia 2013). In
compensated or decompensated cirrhosis, multiple courses of G-
CSF with or without stem or progenitor cell infusion might be
associated with accelerated hepatic regeneration and improved
liver function and survival (Kedarisetty 2015; Verma 2018a; Verma
2018b). Two randomised clinical trials showed that multiple
courses of G-CSF improved survival in people with acute-on-
chronic liver failure (Garg 2012; Duan 2013).
Why it is important to do this review
Studies on the eHects of multiple courses of G-CSF on hepatic
regeneration and function reported conflicting results (Kedarisetty
2015; Lanthier 2018; Newsome 2018; Verma 2018a; Verma 2018b).
A 2014 systematic review, including studies up to July 2013,
concluded that "further robust clinical trials and collaborative
protocols are required" (Moore 2014). We consider it important to
summarise the results of studies assessing the benefits and harms
of G-CSF with or without stem or progenitor cell infusion in people
with chronic advanced liver disease.
O B J E C T I V E S
To assess the benefits and harms of granulocyte colony-stimulating
factor with or without stem or progenitor cell infusion in people
with compensated or decompensated advanced chronic liver
disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised clinical trials, irrespective of publication type,
publication status, and language.
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Types of participants
Adults (18 years of age and older) with the diagnosis of advanced
chronic liver disease (as defined by trialists), either compensated
(i.e. without complications such as gastro-oesophageal varices,
ascites, jaundice, encephalopathy) or decompensated, with one
or more of the above listed complications, or with acute-on-
chronic liver failure (ACLF), as defined according to European
Association for the Study of the Liver (EASL)-Chronic Liver Failure
(CLIF) consortium criteria, that is, "an acute deterioration of pre-
existing chronic liver disease, usually related to a precipitating
event and associated with increased mortality at three months due
to multisystem organ failure" (Arroyo 2017).
Types of interventions
Experimental intervention
G-CSF, independent of the route or schedule of administration, as a
single treatment or combined with stem or progenitor cell infusion
or with other medical co-interventions.
Control intervention
No intervention or placebo.
We will allow collateral interventions if delivered equally to all
participants in the trial groups.
Types of outcome measures
Primary outcomes• All-cause mortality• Proportion of participants with one or more serious adverse
events. We will consider an event as a serious adverse event if
trial authors clearly state that it was due to the experimental
or control intervention, and if it fulfils the definition of
serious adverse events of the International Conference on
Harmonization (ICH) Guidelines (ICH-GCP 1997), that is, any
event that leads to death; is life-threatening; requires in-patient
hospitalisation or prolongation of existing hospitalisation; or
results in persistent or significant disability, congenital birth,
or anomaly; and any important medical event that may have
jeopardised the patient or required intervention to prevent it.
We will consider all other adverse events as non-serious. If an
included study reports only a short list of serious adverse events
that the trialists deem important, we plan to use the highest
reported number. If trialists clearly stated that a death was due
to the experimental or control intervention, we plan to consider
and use this event as a serious adverse event• Health-related quality of life (any validated continuous outcome
scale used by trialists)
Secondary outcomes• Proportion of participants with liver disease-related morbidity
(i.e. proportion of participants who developed one or more
complications such as ascites, variceal bleeding, hepatorenal
syndrome, hepatic encephalopathy, jaundice, or portal
thrombosis, or who underwent liver transplantation)• Proportion of participants with adverse events considered to be
non-serious
• Proportion of participants without improvement in liver
function scores such as Child-Turcotte-Pugh (CTP) or model for
end-stage liver disease (MELD) scores as defined by trialists
We plan to assess all outcomes only at ’maximum follow-up’.
If the time from randomisation to maximum follow-up diHered
significantly between the included trials, then we will do a
subgroup analysis to assess whether the diHerent follow-up
periods aHected our results.
The above listed outcomes will nol be used as criteria for including
studies.
Search methods for identification of studies
Electronic searches
We plan to search: the Cochrane Hepato-Biliary Group Controlled
Trials Register (maintained and searched internally by the CHBG
Information Specialist via the Cochrane Register of Studies Web);
the Cochrane Central Register of Controlled Trials (CENTRAL; latest
issue), in the Cochrane Library; MEDLINE Ovid (1946 to date of
search); Embase Ovid (1974 to date of search); Latin American
Caribbean Health Sciences Literature (LILACS; Bireme; 1982 to
date of search); BIOSIS (Web of Science; 1969 to date of search);
Science Citation Index Expanded (Web of Science; 1900 to date
of search); and Conference Proceedings Citation Index - Science
(Web of Science; 1990 to date of search) (Royle 2003). Appendix 1
presents the preliminary search strategies.
Searching other resources
We also plan to search the bibliographic references of identified
randomised clinical trials and review articles to find randomised
clinical trials not identified by the electronic searches. We will
contact the principal authors of the identified randomised clinical
trials to inquire about additional randomised clinical trials that
they might know of.
We will search Google Scholar, the Turning Research
into Practice (TRIP) database, and on-line trials registries
such as ClinicalTrials.gov, European Medicines Agency (EMA)
(www.ema.europa.eu/ema/), World Health Organization (WHO)
International Clinical Trial Registry Platform (www.who.int/ictrp),
and US Food and Drug Administration (FDA) (www.fda.gov). We
will endeavour to identify randomised clinical trials referenced in
non-English databases, using our personal contacts or local access,
or by asking the CHBG Information Specialist to contact Cochrane
collaborators from around the world with the same intent.
We will search for grey literature in the System for Information on
Grey Literature in Europe - OpenGrey (www.opengrey.eu).
Data collection and analysis
We will prepare the review by following recommendations provided
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2019). We will perform analyses using Review Manager 5
(Review Manager 2014).
If, during the selection of trials, we identify observational studies
such as quasi-randomised or controlled clinical studies with the
same characteristics of participants and interventions as in our
protocol, and reporting adverse events relevant to the outcomes of
this review, we will extract the adverse event data for experimental
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and control groups separately from data for the randomised clinical
trials. We will not specifically search for observational studies
for inclusion in this review, which is a known limitation of the
study in terms of adverse events. We are aware that the decisions
to not search systematically for all observational studies and to
extract data on harm only from quasi-randomised and controlled
clinical studies might bias our review towards assessment of
benefits and might overlook certain harms such as late or rare
harms. If we demonstrate benefits from G-CSF in compensated and
decompensated chronic advanced liver disease, then a systematic
review of the harms of this intervention in observational studies
ought to be launched (Storebø 2018).
Review authors working in pairs will independently extract
the following information: publication data (i.e. year, country,
authors); study characteristics and design; characteristics of trial
participants; trial inclusion and exclusion criteria; interventions;
outcomes; follow-up; types of data analyses (i.e. intention-to-treat,
modified intention-to-treat, per-protocol); and for-profit support.
We will contact trial authors for missing information. We will extract
data at maximum follow-up.
Review authors will resolve disagreements among themselves.
Selection of studies
Two review authors (AC and DP) will independently select
publications on randomised clinical trials relevant to the review.
If a trial is identified as relevant by one review author, but not by
another, the two review authors will discuss the reasoning behind
their decision. If they still disagree, GC will serve as arbitrator.
AC and DP will also scan observational studies retrieved through
searches for a report on adverse events due to the experimental
intervention in this review. If such data are reported, we will use this
information for discussion. None of these studies will be eligible for
inclusion in the review.
Data extraction and management
We plan that two review authors (AC and DP) will independently
extract and validate data. We will use data extraction forms that we
designed and pre-piloted for the purpose. The two review authors
will discuss any disagreement concerning extracted data. If the
review authors still disagree, GC will serve as arbitrator. In cases
where relevant data are not available, we plan to contact the trial
authors.
Assessment of risk of bias in included studies
We plan to assess risk of bias for each primary and secondary
outcome of the included trials (Higgins 2011a; Higgins 2011b). Two
review authors (AC and MF) will independently assess the risk
of bias of each included trial in keeping with recommendations
provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011b), and according to methodological
studies (Schultz 1995; Moher 1998; Kjaergard 2001; Rücker 2008;
Wood 2008; Higgins 2019; Savovic 2012a; Savovic 2012b; Savović
2018). We will use the following definitions in our assessment of risk
of bias.
Allocation sequence generation• Low risk of bias: study authors performed sequence generation
using computer random number generation or a random
numbers table. Drawing lots, tossing a coin, shuHling cards, and
throwing dice are adequate if performed by an independent
person not otherwise involved in the study. In general, we will
classify risk of bias as low if the method used for allocation
concealment suggested that it was extremely likely that the
sequence was generated randomly (e.g. use of interactive voice
response system)• Unclear risk of bias: study authors did not specify the method of
sequence generation• High risk of bias: the sequence generation method was not
random
Allocation concealment• Low risk of bias: participant allocations could not have
been foreseen in advance of, or during, enrolment. A central
and independent randomisation unit controlled allocation.
Investigators are unaware of the allocation sequence (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes)• Unclear risk of bias: study authors did not describe the method
used to conceal the allocation, so intervention allocations may
have been foreseen before, or during, enrolment• High risk of bias: it is likely that investigators who assigned
participants knew the allocation sequence. We will exclude such
quasi-randomised studies
Blinding of participants and personnel• Low risk of bias: blinding of participants and key study personnel
was ensured, and it was unlikely that the blinding could have
been broken; or rarely, no blinding or incomplete blinding, but
review authors judged that the outcome was not likely to be
influenced by lack of blinding• Unclear risk of bias: either of the following: insuHicient
information to permit judgement of 'low risk' or 'high risk'; or
the trial did not address this outcome• High risk of bias: either of the following: no blinding or
incomplete blinding, and the outcome was likely to be
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding
Blinded outcome assessment• Low risk of bias: blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken; or rarely, no
blinding of outcome assessment, but review authors judged that
the outcome measurement was not likely to be influenced by
lack of blinding• Unclear risk of bias: either of the following: insuHicient
information to permit judgement of 'low risk' or 'high risk'; or
the trial did not address this outcome• High risk of bias: either of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to be influenced by
lack of blinding
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Incomplete outcome data• Low risk of bias: missing data were unlikely to make treatment
eHects depart from plausible values. The study used suHicient
methods, such as multiple imputation, to handle missing data• Unclear risk of bias: information was insuHicient to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias on the results• High risk of bias: results were likely to be biased due to missing
data
Selective outcome reporting• Low risk: the trial reported as a primary outcome all-cause
mortality, which is the main reason for treatment with G-CSF
for people with chronic advanced liver disease. If the original
trial protocol was available, the outcomes should have been
those called for in that protocol. If the trial protocol was obtained
from a trial registry (e.g. ClinicalTrials.gov), the outcomes sought
should have been those enumerated in the original protocol if
the trial protocol was registered before or at the time the trial
was begun. If the trial protocol was registered aRer the trial was
begun, those outcomes will not be considered to be reliable• Unclear risk of bias: not all pre-defined or clinically relevant and
reasonably expected outcomes were reported fully, or it was
unclear whether or note data on these outcomes were recorded• High risk of bias: all-cause mortality or one or more pre-defined
outcomes were not reported, despite the fact that data on these
outcomes should have been available and even recorded
Bias at outcome level
We will classify an outcome in a trial to be at low risk of bias if
allocation sequence generation; allocation concealment; blinding
of participants, healthcare professionals, and outcome assessors;
incomplete outcome data; and selective outcome reporting (at the
outcome level) are at low risk of bias for objective and subjective
outcomes (Savović 2018).
Overall bias assessment• Low risk of bias: all domains in a trial are classified at low risk of
bias according to the definitions described above• High risk of bias: one or more of the bias domains in a trial are
classified at unclear or high risk of bias
Measures of treatment e8ect
We plan to present risk ratios (RRs) with 95% confidence intervals
(CIs) for dichotomous outcomes. For continuous outcomes, we
will use mean diHerences (MDs) between experimental and
control groups with their 95% CIs. If studies report quality of
life measurements using diHerent tools, we will calculate the
standardised mean diHerence (SMD) with 95% CI, rather than the
MD. For interpreting SMDs, we plan to use the Cohen’s eHect sizes
rule, which considers 0.2 as a small eHect, 0.5 as a moderate eHect,
and 0.8 as a large eHect (Cohen1988).
Unit of analysis issues
We do not expect to find trials of parallel-group design with more
than two intervention groups. However, if we find trials with more
than two intervention groups, we will combine groups, as sensible,
to create a single pair-wise comparison (Higgins 2019). We do not
expect to find cluster-randomised or cross-over trials. However,
if we find cluster-randomised trials, we will analyse and assess
the risk of bias of cluster-randomised trials separate from that of
the randomised parallel-group clinical trials included in our review
(Higgins 2019). If we find cross-over trials, we will use for analysis
only the first trial period to avoid the cross-over eHect of the
intervention (Higgins 2019).
Dealing with missing data
We plan to contact investigators of the trials to request missing
data. We will perform our analyses according to the intention-to-
treat analysis method, that is, by analysing participants in the trials
in the groups to which they were randomised, regardless of whether
they had received or adhered to the allocated intervention. If data
are not available and we receive no reply from study authors, we
will use the data as reported.
For our dichotomous outcome 'all-cause mortality', we plan to
conduct the sensitivity analyses described below.
• 'Extreme-case' analysis favouring the experimental intervention
(’best-worse’ case scenario): none of the participants who
dropped out from the experimental group experienced the
outcome, but all participants who dropped out from the control
group experienced the outcome; including all randomised
participants in the denominator.• 'Extreme-case' analysis favouring the control (’worst-best’
case scenario): all participants who dropped out from the
experimental group, but none from the control group,
experienced the outcome; including all randomised participants
in the denominator.
For the continuous outcome 'health-related quality of life', if the
trial does not report standard deviations, we plan to impute
standard deviations according to Higgins 2019.
Assessment of heterogeneity
We plan to explore the presence of statistical heterogeneity
by using the Chi2 test, with significance set at P value less
than 0.10. In addition, we will use the I2 statistic to quantify
heterogeneity according to the following classification: from 0%
to 40%, heterogeneity may not be important; from 30% to 60%,
heterogeneity may be moderate; from 50% to 90%, heterogeneity
may be substantial; and from 75% to 100%, heterogeneity may be
considerable (Deeks 2019).
Assessment of reporting biases
For any considered outcome when at least 10 trials are included in
the meta-analysis, we will test for funnel plot asymmetry (Higgins
2019).
Data synthesis
Meta-analysis
We plan to perform meta-analyses in keeping with
recommendations provided in the Cochrane Handbook for
Systematic Reviews of Intervention (Deeks 2019). We will use the
statistical soRware Review Manager 5 provided by Cochrane to
analyse data (Review Manager 2014). We will apply both fixed-eHect
(DeMets 1987) and random-eHects models (DerSimonian 1986)
meta-analyses. We will consider the fixed-eHect model only as a
sensitivity analysis.
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Subgroup analysis and investigation of heterogeneity
We plan to conduct the following subgroup analyses.
• Trials at low risk of bias compared to trials at high risk of
bias (because trials at high risk of bias may overestimate or
underestimate intervention eHects).• Trials at risk of for-profit support compared to trials without
for-profit support (because trials with for-profit support may
overestimate or underestimate intervention eHects).• Trials including decompensated cirrhosis compared to trials
including only compensated chronic liver disease (because
eHects of treatment might vary according to the severity of liver
dysfunction).• Trials including only or mainly participants with alcoholic liver
disease compared to trials including only or mainly participants
with other liver disease of other origins (because eHects of
treatment might vary according to the cause).• Trials using dosage below the recommended dosage of G-CSF
for peripheral cell mobilisation (5 mcg/kg daily for at least five
consecutive days) compared to trials using equivalent or higher
dosage (lower dosages are expected to be ineHective).• Trials using daily dosage of G-CSF > 10 mcg/kg daily compared
to trials using lower dosage (because below this dose, eHects of
treatment might be impaired).• Trials using short-term treatment schedule shorter than seven
days compared to trials using longer treatment schedules
(longer than seven days) (because shorter treatment might
reduce eHects of treatment).• Trials combining G-CSF with other medical co-intervention
compared to trials using only G-CSF (because any co-
intervention might influence eHects of treatment).• Trials combining G-CSF with stem or progenitor cell infusion
compared to trials using only G-CSF (because infusion of stem or
progenitor cells might modify eHects of treatment).
Additional subgroup analyses may be considered at the review
stage. Due to the large number of subgroup analyses, we will
interpret them conservatively.
Sensitivity analysis
In addition to the two sensitivity analyses specified in Dealing with
missing data, we plan to perform the following sensitivity analyses.
• Assessing the robustness of our results by including only trials
reporting intention-to-treat analyses.• Assessing eHects of risk of bias of included trials by performing
a sensitivity analysis from which we will exclude trials classified
at high risk of bias.• Comparing fixed-eHect and random-eHects estimates of the
intervention eHect to assess the influence of small-study eHects
on the results of our meta-analysis.• Comparing our assessment of imprecision with GRADE to
that performed with the Trial Sequential Analysis (see below)
(Castellini 2018; Gartlehner 2018).
Trial Sequential Analysis
We plan to perform Trial Sequential Analysis on the primary
outcomes to calculate the cumulative sample size of the meta-
analysis (information size) and to reduce the risk of random errors
due to sparse data and repetitive testing of accumulating data
(Wetterslev 2008; Thorlund 2011). We will calculate the information
size adjusted for heterogeneity (diversity, D2) between trials using
the following parameters (Wetterslev 2009): proportion of events in
the control group estimated from the included trials (overall mean
value); anticipated intervention eHect (relative risk reduction, RRR)
of 15%; alpha of 2.5%, as we use three primary outcomes; and
beta of 10% (Jakobsen 2014; Wetterslev 2017). We will add trials
to the analysis according to the year of publication. If more
than one trial was published in a year, we will add the trials in
alphabetical order, according to the name of the first author. On
the basis of the required information size, we will construct the trial
sequential monitoring boundaries for benefits and futility using the
O'Brien-Fleming alpha spending (for benefit) and beta-spending
(for futility) functions. The boundaries for benefit are used for
meta-analyses that have not reached the required information size
to conclude when statistical significance is reached. If the trial
sequential monitoring boundary is crossed before the required
information size is reached, a suHicient level of evidence is reached,
results of the meta-analysis can be considered conclusive if bias can
be excluded, and no additional trials may be needed. Conversely, if
the boundary is not crossed, the meta-analysis is inconclusive, and
more trials may be needed to detect or reject a certain intervention
eHect. When the cumulative Z-curve crosses the futility boundaries,
a suHicient level of evidence is reached that the two treatments
do not diHer by more than 15% (anticipated intervention eHect
used in information size estimation), and no additional trials may
be needed. In all situations where no trial sequential monitoring
boundaries are reached, further studies may be needed until the
information size is reached, or until monitoring boundaries are
crossed.
We will perform Trial Sequential Analysis with Trial Sequential
Analysis soRware, version 0.9.5.10 beta (TSA 2011).
Summary of findings
We will create a 'Summary of findings' table including the following
outcomes: all-cause mortality; proportion of participants with one
or more serious adverse events; health-related quality of life; and
proportion of participants with liver disease-related morbidity. We
will report the longest follow-up with a range of follow-up for each
outcome.
We will use the GRADE approach and soRware to assess the
quality of a body of evidence (GRADEpro GDT). GRADE considers
the following criteria: study risk of bias (methodological quality);
inconsistency of results (unexplained heterogeneity); indirectness
of evidence (population, intervention, comparator, or outcome);
imprecision of results (wide CIs); and publication bias. We will
define levels of certainty as 'high', 'moderate', 'low', or 'very low' as
follows.
• High certainty: we are very confident that the true eHect lies
close to that of the estimate of the eHect.• Moderate certainty: we are moderately confident in the eHect
estimate: the true eHect is likely to be close to the estimate of the
eHect, but there is a possibility that it is substantially diHerent.• Low certainty: our confidence in the eHect estimate is limited:
the true eHect may be substantially diHerent from the estimate
of the eHect.
Granulocyte colony-stimulating factor with or without stem or progenitor cell infusion for people with compensated or decompensated
advanced chronic liver disease (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Very low certainty: we have very little confidence in the eHect
estimate: the true eHect is likely to be substantially diHerent
from the estimate of eHect.
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Database Time span Search strategy
The Cochrane He-
pato-Biliary Group
Controlled Trials
Register
Date will be given
at review stage
(colony-stimulating factor or G-CSF or GCSF or CSF3 OR CSF 3 or filgrastim or lenograstim)
and (advanc* and chronic and (liver* or hepat*))
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Cochrane Cen-
tral Register of
Controlled Trials
(CENTRAL), in the
Cochrane Library
Latest issue #1 MeSH descriptor: [Granulocyte Colony-Stimulating Factor] explode all trees
#2 colony-stimulating factor or G-CSF or GCSF or CSF3 OR CSF 3 or filgrastim or lenogras-
tim
#3 #1 or #2
#4 (advanc* and chronic and (liver* or hepat*))
#5 #3 and #4
MEDLINE Ovid 1946 to date of
search
1. exp Granulocyte Colony-Stimulating Factor/
2. (colony-stimulating factor or G-CSF or GCSF or CSF3 or CSF 3 or filgrastim or lenogras-
tim).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, floating sub-heading word, keyword heading word, protocol supplementary con-
cept word, rare disease supplementary concept word, unique identifier, synonyms]
3. 1 or 2
4. (advanc* and chronic and (liver* or hepat*)).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary con-
cept word, unique identifier, synonyms]
5. 3 and 4
Embase Ovid 1974 to date of
search
1. exp granulocyte colony stimulating factor/
2. (colony-stimulating factor or G-CSF or GCSF or CSF3 or CSF 3 or filgrastim or lenogras-
tim).mp. [mp=title, abstract, heading word, drug trade name, original title, device man-
ufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
3. 1 or 2
4. (advanc* and chronic and (liver* or hepat*)).mp. [mp=title, abstract, heading word,
drug trade name, original title, device manufacturer, drug manufacturer, device trade
name, keyword, floating subheading word, candidate term word]
5. 3 and 4
LILACS (Bireme) 1982 to date of
search
colony-stimulating factor or G-CSF or GCSF or CSF3 OR CSF 3 or filgrastim or lenograstim)
[Words] and (advanc$ and chronic and (liver$ or hepat$)) [Words]
BIOSIS (Web of
Science)
1969 to date of
search
#3 #2 AND #1
#2 TS=(advanc* and chronic and (liver* or hepat*))
#1 TS=(colony-stimulating factor or G-CSF or GCSF or CSF3 OR CSF 3 or filgrastim or
lenograstim)
Science Citation
Index Expanded
(Web of Science)
1900 to date of
search
#3 #2 AND #1
#2 TS=(advanc* and chronic and (liver* or hepat*))
#1 TS=(colony-stimulating factor or G-CSF or GCSF or CSF3 OR CSF 3 or filgrastim or
lenograstim)
Conference Pro-
ceedings Citation
Index – Science
(Web of Science)
1990 to date of
search
#3 #2 AND #1
#2 TS=(advanc* and chronic and (liver* or hepat*))
  (Continued)
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#1 TS=(colony-stimulating factor or G-CSF or GCSF or CSF3 OR CSF 3 or filgrastim or
lenograstim)
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